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Correct antibiotic treatment is of utmost importance to
treat infections in critically ill patients, not only in terms
of spectrum and timing but also in terms of dosing.
However, this is a real challenge for the clinician because
the pathophysiology (such as shock, augmented renal
clearance, and multiple organ dysfunction) has a major
impact on the pharmacokinetics of hydrophilic
antibiotics. The presence of extra-corporal circuits, such
as continuous renal replacement therapy, may further
complicate this difficult exercise. Standard dosing may
result in inadequate concentrations, but unadjusted
dosing regimens may lead to toxicity. Recent studies
confirm the variability in concentrations, and the wide
variation in dialysis techniques used certainly contributes
to these findings. Well-designed clinical studies are
needed to provide the data from which robust dosing
guidance can be developed. In the meantime,
non-adjusted dosing in the first 1 to 2 days of antibiotic
therapy during continuous renal replacement therapy
followed by dose reduction later on seems to be a
prudent approach.Several studies have addressed this issue in recentThis commentary discusses the findings of Beumier and
colleagues [1] about beta-lactam concentrations during
continuous renal replacement therapy (CRRT). In recent
years, pharmacokinetics (PK) of antibiotics in critically
ill patients has been studied intensely. Standard anti-
biotic dosing apparently results in highly variable anti-
biotic concentrations in the blood and tissues. A recent
multicenter point prevalence study found that 20% of* Correspondence: jan.dewaele@ugent.be
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2014the patients are underdosed (when aiming for the most
conservative target) and could link antibiotic under-
exposure to worse clinical outcome [2]. The causes for
the variability in effective antibiotic concentration are
multiple, but increased volume of distribution and en-
hanced elimination from the circulation, mostly via the
kidneys in patients suffering from augmented renal
clearance, are the most important contributors.
But also when the kidneys fail, antibiotic dosing can be
challenging. When kidney function deteriorates, stand-
ard dosing may lead to accumulation of a drug and
therefore antibiotic doses are often adapted to the kid-
ney function. Also, when renal replacement therapy
(RRT) is indicated, antibiotic doses are often decreased.
RRT does, however, affect antibiotic concentrations as
antibiotics are also eliminated from the circulation. The
rate at which this occurs is affected by the physicochem-
ical characteristics of the drug and the type and intensity
of RRT used, among other factors. Antibiotics with a
small volume of distribution and low protein binding
will be affected more. It can be expected that CRRT
techniques are more efficient in removing antibiotics
from the blood.
years. Seyler and colleagues [3] found that patients
treated with CRRT had overall low target attainment in
the early phase of therapy when recommended doses are
used and when four times the minimum inhibitory con-
centration (MIC) of the least susceptible microorganism
is aimed for [3]. Later during therapy, concentrations
were higher for meropenem, piperacillin, and ceftazi-
dime - in all patients, these drugs were administered as
intermittent infusion. Bauer and colleagues [4] found
that there was an important interindividual variability in
piperacillin concentrations and that CRRT dose was the
only factor associated with piperacillin elimination. ThisCentral Ltd. The licensee has exclusive rights to distribute this article, in any
ion. After this time, the article is available under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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in a similar patient cohort, with both under- and over-
dosing occurring in about 10% of the patients, depend-
ing on the PK/pharmacodynamics (PD) target
considered. In all of these studies, the variability of anti-
biotic doses administered is striking; this, on the one
hand, reflects the uncertainty of the clinician on how
RRT may affect antibiotic concentrations but, on the
other hand, adds a level of complexity when it comes to
analyzing target attainment in different studies. Further-
more, the intervals between start of antibiotic therapy
and sampling as well as RRT initiation and sampling are
additional confounders when target attainment is ana-
lyzed in these studies. In a systematic review, Vaara and
colleagues [6] found the overall quality of studies investi-
gating the effect of RRT moderate, as the many import-
ant RRT parameters were often lacking.
In this issue of Critical Care, Beumier and colleagues
[1] report that standard, unadjusted dosing results in
very high concentrations in about half of the patients.
Although the study includes a large number of patients
and reflects clinical practice in their intensive care unit,
there may have been a selection bias with only patients
at risk selected for therapeutic drug monitoring (TDM).
Also, the timing was variable, and it is not clear whether
patients that were treated with antibiotics long before
RRT was initiated had an increased risk of overdosing as
it was defined in this study.
With these new data, drawing firm conclusions regard-
ing antibiotic dosing during RRT remains difficult. How-
ever, it can be concluded that higher-than-standard
dosing in this patient population is probably unwar-
ranted. From previous studies, it seems that underdosing
is more common during the first days of treatment and
that overdosing may occur later (48 hours or later) when
doses are not adjusted. This is probably due to the fact
that factors other than RRT determine the concentra-
tions in the first 24 to 48 hours of therapy, such as the
enhanced volume of distribution, and elimination deter-
mines the subsequent concentrations. Furthermore, it
should be kept in mind that the susceptibility of the
microorganism is equally important; target attainment is
in danger only when borderline susceptible microorgan-
isms with higher-than-average MIC are involved.
Clearly, more research using well-designed studies
with prospective data collection is needed. Moreover, the
impact of other RRT strategies such as intermittent
hemodialysis and sustained low-efficiency daily dialysis
needs our urgent attention. In the meantime, for pa-
tients undergoing CRRT, optimizing antibiotic therapy is
as essential as in other patients. Though rarely suggested
in CRRT, prolonged and extended infusion may be suffi-
cient to overcome underdosing in many. In difficult
cases, TDM - when available - could be a solution,although many questions surrounding the application of
TDM remain unanswered. Most importantly, it is not
clear what PK/PD target should be aimed for to treat in-
fections during critical illness, but TDM could at least
detect the extremes of concentrations and allow dose
adaptation in case of severe under- and overdosing.
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